You are here: Industry Insights > ViiV Healthcare

News List

FDA approves ViiV's novel HIV treatment Rukobia pharmatimes
July 03, 2020
The US Food and Drug Administration (FDA) has approved ViiV Healthcare's novel attachment inhibitor Rukobia (fostemsavir) expanding treatment options for HIV.
ViiV selects projects for HIV/COVID-19 response fund pharmatimes
July 02, 2020
ViiV Healthcare has announced that 109 projects from 26 countries are to get financial support from its Global HIV and COVID-19 Emergency Response Fund.
FDA approves ViiV Healthcare’s Tivicay to treat HIV in children pharmaceutical-technology
June 16, 2020
ViiV Healthcare has received approval from the US Food and Drug Administration (FDA) for Tivicay PD (dolutegravir) tablets, in combination with other antiretroviral agents, to treat children with human immunodeficiency virus type 1 (HIV-1) infection.
ViiV HIV prevention trial stopped early on efficacy pharmatimes
May 19, 2020
ViiV Healthcare's trial assessing an investigational, long-acting injection for HIV prevention has been stopped early due to high levels of efficacy.
ViiV Healthcare secures Canadian approval for HIV drug regimen CABENUVA pharmaceutical-business-review
March 25, 2020
ViiV Healthcare has secured approval for CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions) from Health Canada for the treatment of HIV-1 infection in adults.
ViiV Healthcare, Janssen get Canadian approval for Cabenuva pharmaceutical-technology
March 24, 2020
ViiV Healthcare and Janssen Pharmaceutical have announced the Health Canada approval of Cabenuva as a once-monthly, long-acting therapy for adults with HIV-1 infection.
ViiV Healthcare and UNC-Chapel Hill expand HIV cure partnership pharmaceutical-technology
March 11, 2020
Glaxo-Smith-Kline’s human immunodeficiency virus (HIV) specialist company ViiV Healthcare has renewed its public-private research partnership with University of North Carolina at Chapel Hill (UNC-Chapel Hill) for another five years with a $20m investment.
ViiV Healthcare secures Japanese approval for Dovato to treat HIV-1 infection pharmaceutical-business-review
January 19, 2020
Specialist HIV company ViiV Healthcare has secured Japanese approval for Dovato (dolutegravir 50mg/lamivudine 300mg) two-drug regimen to treat of HIV-1 infection.
ViiV Healthcare seeks FDA approval for fostemsavir to treat HIV-1 infection pharmaceutical-business-review
December 11, 2019
ViiV Healthcare is seeking approval from the US Food and Drug Administration (FDA) for its fostemsavir to treat HIV-1 infection.
ViiV Healthcare receives MA in Europe for Dovato pharmaceutical-technology
July 04, 2019
The European Commission (EC) has approved ViiV Healthcare’s marketing authorisation application (MAA) for Dovato (dolutegravir/lamivudine), which is indicated to treat HIV-1 infection.

Previous page 1 2 3 Next page